A Global Intellectual Property Waiver is Still Needed to Address the Inequities of Covid-19 and Future Pandemic Preparedness
Bibliographic Data
| ID | 13775423 |
|---|---|
| Authors | Tahir Amin (Initiative for Medicines, Access and Knowledge (I-MAK), New York City, NY, USA, corresponding author), Aaron S Kesselheim (0000-0002-8867-2666, Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Deparment of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA) |
| Year | 2022 |
| Volume | 59 |
| Pages | 469580221124821-469580221124821 |
| Publication date | 2022-01-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | INQUIRY The Journal of Health Care Organization Provision and Financing (JOURNAL) |
| Journal identifiers | ISSN: 0046-9580 • E-ISSN: 1945-7243 |
| Publisher | SAGE Publishing (PUBLISHER • US) |
| DOI | 10.1177/00469580221124821 |
| PMID | 36124939 |
| OpenAlex | W4296502899 |
| Language | EN |
| Citations received | 8 |
| References cited | 3 |
In October 2020, India and South Africa submitted a proposal to the World Trade Organization (WTO) to suspend IP on all COVID-19 vaccines, therapeutics, and diagnostics until widespread vaccination could help achieve immunity among people in low- and middle-income countries. After 18 months, the final WTO Decision substantially watered down the original text proposed by India and South Africa, limiting it only to patents on vaccines and the use of protected clinical trial data for regulatory approval. We address why an IP waiver under TRIPS consistent with the one originally proposed by India and South Africa is still needed to not only meet the ongoing inequities of COVID-19, but also to ensure the right precedent for future equitable pandemic preparedness and other crises affecting the global South. To meet the multilateral goals of the WTO, an IP waiver as proposed by India and South Africa is still needed to increase manufacturing capability for vaccines, therapeutics, and other COVID-19 health-related technologies
Business · Coronavirus disease 2019 (COVID-19 · Development economics · Disease · Economic growth · Economics · Global health · Health care · Infectious disease (medical specialty · Intellectual property · International trade · Pandemic · Political science · Preparedness · TRIPS Agreement · TRIPS architecture · Waiver · Biotechnology and Related Fields · Innovation and Socioeconomic Development · Law · Medicine · Pharmaceutical Economics and Policy
The World Health Organization was born as a normative agency
Is heterologous prime-boost Covid-19 vaccination a concern or an opportunity for Ethiopia
Global health security and the health-security nexus
Mpox and the Ethics of Outbreak Management
Navigating Energy and Climate Transitions
Global inequities in access to Covid-19 health products and technologies
World-System of Vaccine Distribution
Health equity and the global social contract
| Unique citing works | 8 |
|---|---|
| Citations per year | 2.67 |
| Citation span | 2023 - 2026 (4) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 7 |